Free Trial
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

$16.38
-0.27 (-1.62%)
(As of 04:26 PM ET)
Today's Range
$16.32
$16.68
50-Day Range
$15.74
$17.40
52-Week Range
$7.95
$17.69
Volume
8.15 million shs
Average Volume
10.35 million shs
Market Capitalization
$18.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.56

Teva Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
13.1% Upside
$18.56 Price Target
Short Interest
Healthy
1.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$9.35 M Sold Last Quarter
Proj. Earnings Growth
12.93%
From $2.32 to $2.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.41 out of 5 stars

Medical Sector

296th out of 914 stocks

Pharmaceutical Preparations Industry

131st out of 433 stocks

TEVA stock logo

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TEVA Stock Price History

TEVA Stock News Headlines

Generic drugs and pill bottles
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year.
Generic drugs and pill bottles
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Human testing is the last step before this company goes big
Biotech innovations have the potential to change the world. And help you build wealth in the process.
3 No-Brainer Stocks to Buy With $200 Right Now
Human testing is the last step before this company goes big
Biotech innovations have the potential to change the world. And help you build wealth in the process.
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/17/2024
Next Earnings (Confirmed)
7/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
37,851
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.56
High Stock Price Target
$24.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+12.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-559,000,000.00
Pretax Margin
-5.12%

Debt

Sales & Book Value

Annual Sales
$15.85 billion
Cash Flow
$3.39 per share
Book Value
$7.25 per share

Miscellaneous

Outstanding Shares
1,132,640,000
Free Float
1,126,411,000
Market Cap
$18.68 billion
Optionable
Optionable
Beta
0.90
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

TEVA Stock Analysis - Frequently Asked Questions

How have TEVA shares performed this year?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA stock has increased by 57.1% and is now trading at $16.40.
View the best growth stocks for 2024 here
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Wednesday, May, 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by $0.03. The firm earned $3.82 billion during the quarter, compared to the consensus estimate of $3.70 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 37.33% and a negative net margin of 2.88%.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' top institutional shareholders include Bourgeon Capital Management LLC (0.06%), SG Americas Securities LLC (0.06%), Baader Bank Aktiengesellschaft (0.02%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Roberto Mignone, Mark Sabag, Sven Dethlefs, Eliyahu Sharon Kalif, Richard D Francis, David Matthew Stark, Amir Weiss, Eric Drape, Hafrun Fridriksdottir, Vikki L Conway, Eli Shani and Eric A Hughes.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC) and Micron Technology (MU).

This page (NYSE:TEVA) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners